Many patients with idiopathic Parkinson disease (PD) experience deficits in executive skills (ES; eg, attentional control, self-monitoring), which are associated with a range of impairing symptoms such as visual hallucinations, decreased motor control, and increased apathy. Pharmacological methods for improving ES in PD have shown to be somewhat unreliable. The goal of this study was to evaluate the feasibility and patient acceptance of a nonpharmacological cognitive remediation program that aimed to improve sustained, selective, alternating, and divided attentional abilities in a sample of 16 nondemented PD patients. Based on ratings of 4 feasibility dimensions (fatigue, effort, progress, enjoyment), patients with PD demonstrated a high degree of acceptance and successfully engaged in the program. As predicted, ratings of progress differed significantly across tasks according to difficulty level and were positively related to posttraining improvement in ES. Fatigue ratings showed negative associations with other indices across task types, suggesting that monitoring fatigue during cognitive remediation is essential. Patients’ ratings of enjoyment did not correspond to task difficulty, indicating that tasks could be simultaneously challenging and rewarding. Males reported exerting greater effort during the training than females. It was concluded that the intervention is appropriate for testing in a randomized controlled trial.
Norman DA, Shallice T.Attention to action: Willed and automatic control of behavior. In: Davidson RJ, Schwarts GE , Shapiro D, eds. Consciousness and self-regulation: Advances in research and therapy. New York, NY: Plenum Press;1986 :1-18.
Muslimovic D. , Post B., Speelman JD, Schmand B.Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239-1245.
5.
Leroi I., Collins D., Marsh L.Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson’s disease: a review. J Neurol Sci. 2006;248(1):104-114.
6.
Thommessen B. , Aarsland D., Braekhus A., Oksengaard AR, Engedal K., Laake K.The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson’s disease. Int J Geriatr Psychiatry. 2002;17(1):78-84.
7.
Fenelon G., Mahieux F., Huon R., Ziegler M.Hallucinations in Parkinson’s disease: Prevalence, phenomenology and risk factors. Brain. 2000;123(4):733-745.
8.
Schrag A., Jahanshahi NQWhat contributes to quality of life in patients with Parkinson’s disease ? J Neurol Neurosurg Psychiatry. 2004;69(3):308-312.
9.
Zgaljardic DJ , Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson’s disease. J Clin Exp Neuropsychol. 2006;28(7):1127-1144.
10.
Bassett SSCognitive impairment in Parkinson’s disease. Prim psychiatry . 2005;12(7):50-55.
11.
Klepac N., Hajnsek S., Trkulja V.Cognitive performance in nondemented nonpsychotic Parkinson disease patients with or without a history of depression prior to the onset of motor symptoms . J Geriatr Psychiatry Neurol.2010;23(1):15-26.
12.
Kummer A., Hars·nyi E, Dias F., Cardoso F., Caramelli P., Teixeira ALDepression impairs executive functioning in Parkinson disease patients with low educational level. Cogn Behav Neurol.2009;22(3):167-172.
13.
Ryder KA, Gontkovsky ST, McSwan KL, Scott JG, Bharucha KJ, Beatty WWCognitive function in Parkinson’s Disease: Association with anxiety but not depression. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2002;9(2):77-84.
14.
Alexopoulos GS, Kiosses DN, Klimstra S., Kalayam B.Clinical presentation of the ‘‘depression-executive dysfunction syndrome’’ of late life. Am J Geriatr Psychiatry. 2002;10(1):98-106.
15.
Mohlman J., Gorman JMThe role of executive functioning in CBT: a pilot study with anxious older adults. Behav Res Ther. 2005;43(4):447-465.
16.
Potagas C., Papageorgiou S.Phenomenology and management of cognitive and behavioral disorders in Parkinson’s disease. Rise and logic of dementia in Parkinson’s disease. Annals Gen Psychiat. 2006;5(12):1-9.
17.
Arciniegas DB, Beresford TPNeuropsychiatry: An introductory approach. Cambridge, UK : Cambridge University Press; 2001 .
18.
Linazasoro G. , Lasa A., Van Blercom N.Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin Neuropharmacol. 2005;28(4): 176-178.
19.
Rektorova I. , Rektor I., Bares M., et al. Cognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurology. 2005;12(1):9-15.
20.
Grace J., Amick MM, Friedman JHA double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008 ;80(1):18-23.
21.
Leroi I., Brandt J., Reich SG, Lyketsos CG, Grill S., Thompson R., Marsh L.Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry. 2002;19(1):1-8.
22.
Witt K., Pulkowski U., Herzog J., et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol. 2004;61(5):697-700.
23.
Zahodne LB, Okun MS, Foote KD, et al. Cognitive declines one year after unilateral deep brain stimulation surgery in parkinson’s disease: a controlled study using reliable change . Clin Neuropsychol.2009;23(3):385-405.
24.
Ball K., Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA. 2002;288(18):2271-2281.
25.
Butti G., Buzzelli S., Fiori M., Giaquinto S.Observations on mentally impaired elderly patients treated with THINKable, a computerized cognitive remediation. Arch Gerontol Geriatr . 1998;26(suppl 1):49-56.
26.
Gordon WA, Hibbard MRCritical issues in cognitive remediation. Neuropsychology . 1992;6(4):361-370.
27.
Raskin SACognitive remediation of mild traumatic brain injury in an older age group . In: Raskin SA, Mateer CA, eds. Neuro-psychological management of mild traumatic brain injury. New York, NY: Oxford University Press;2000:254-268.
28.
Sinforiani E., Banchieri L., Zucchella C., Pacchetti C., Sandrini G.Cognitive rehabilitation in Parkinson’s disease. Arch Gerontol Geriatr. 2004;9(suppl):387-391.
29.
Sammer G., Reuter I., Hullman K., Kaps M., Vaitl D.Training of executive functions in Parkinson’s disease. J Neurolog Sci. 2006;248(1):115-119.
30.
Sohlberg MM, Johnson L., Paule L., Raskin SA, Mateer CAAPT-II: A program to address attentional deficits for persons with mild cognitive dysfunction. Wake Forest, NC: Lash & Associates;2001.
31.
Silverstein SM, Hatashita-Wong M., Solar BA, et al. Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. Psychol Med. 2005;35(6):829-837.
32.
Sohlberg MM , McLaughlin KA, Pavese A., Heidrich A., Posner MIEvaluation of attention process training and brain injury education in persons with acquired brain injury. J Clin Exp Neuropsychol. 2000;22(5):656-676.
33.
Mohlman J.More power to the executive? CBT plus executive training for late life generalized anxiety disorder. Cogn Behav Pract. 2008;15:306-316.
34.
Berridge KC , Robinson TEWhat is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?Brain Res Rev. 1998;28(3):309-369.
35.
Mattox ST, Valle-Inclan F., Hackley SAPsychophysiological evidence for impaired reward anticipation in Parkinson’s disease. Clin Neurophysiol. 2006;117(10):2144-2153.
36.
Czernecki V. , Pillon B., Houeto JL, Pochon JB, Levy R., Dubois B.Motivation, reward, and Parkinson’s Disease: Influence of dopatherapy. Neuropsychologia. 2002;40(13):2257-2267.
37.
Hart RP, Wade JB, Calabrese VP, Colenda CCVigilance performance in Parkinson’s disease and depression. J Clin Exp Neuropsychol. 1998;20(1):111-117.
38.
Pallier G.Gender differences in the self-assessment of accuracy on cognitive tasks. Sex Roles. 2003;48(5-6):265-276.
39.
Folstein MF , Folstein SE, McHugh PR "Mini-mental state:’’ A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
40.
Meyer T., Miller M., Metzger R., Borkovec TDDevelopment and validity of the Penn State Worry Scale. Behav Res Ther. 1990; 28(6):487-495.
41.
Beck AT, Steer RAManual for the Beck Anxiety Inventory. San Antonio, TX : Psychological Corporation; 1990 .
42.
Spielberger C. , Gorsuch R., Lushene R.State-Trait Anxiety Inventory: Test Manual . Palo Alto, CA: Consulting Psychologists ; 1983.
43.
Beck AT, Steer RAManual for the Beck Depression Inventory. San Antonio, TX: Psychological Corporation; 1987 .
44.
Hamilton M.The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
45.
Hamilton M.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
46.
Kaplan E., Goodglass H., Weintraub S.Boston Naming Test (revised 60-item version). Philadelphia : Lea & Febiger; 1983.
47.
Wechsler D.Wechsler Adult Intelligence Scale and Wechsler Memory Scale Technical Manual . 3rdSan Antonio, TX: The Psychological Corporation; 1997.
Army Individual TestBattery AIT.Manual ofdirections andscoring. Washington, DC: War Department, Adjutant General’s Office; 1944.
50.
Miller E.Verbal fluency as a function of a measure of verbal intelligence in relation to different types of pathology. Br J Clin Psychol. 1984;23(1):53-57.
51.
Shohamy D., Myers C., Onalor S., Gluck MARole of basal ganglia in category learning: how do patients with Parkinson’s disease learn? Behav Neurosci. 2004;118(4):676-686.
52.
Mohlman J., Hunter-Reel D., Chazin D., et al. A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease. Clin Case Stud. 2010;9(1):74-90.
53.
Deci EL, Koestner R., Ryan RMA meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic motivation. Psychol Bull. 1999 ;125(6):627-668.
54.
Abe K., Takanashi M., Yanagihara T.Fatigue in patients with Parkinson’s disease. Behav Neurol. 2000;12(3):103-106.
55.
Frasier LD, Cotrell V., Hooker K.Possible selves and illness: a comparison of individuals with Parkinson’s disease, early-stage Alzheimer’s disease, and healthy older adults. Int J Behav Dev. 2003;27(1):1-11.
56.
Zimmerman BJSelf-efficacy: an essential motive to learn . Con-temp Educ Psychol. 2000;25(1):82-91.
57.
Rose D., Wykes T., Farrier D., Doran AM, Sporle T., Bogner D.What do clients think of cognitive remediation therapy? A consumer-led investigation of satisfaction and side effects. Am J Psychiatr Rehabil. 2008;11(2):181-204.
